'Grand Slam' Pancreatic Cancer Drug Wins FDA Approval
(MedPage Today) -- The FDA approved the first-in-class RAS inhibitor daraxonrasib (Rasonque) for metastatic pancreatic ductal adenocarcinoma (PDAC), the most common form of pancreatic cancer. The approval stipulates use in adults with PDAC previously...
We haven't written up this one. MedPage Today has the full story — the link below goes straight to it.